Please provide your email address to receive an email when new articles are posted on . Trumenba, a bivalent meningococcal B vaccine, is safe and immunogenic in adolescents and young adults after two ...

Teaching kids to share is usually a parental goal, but a new ad from Pfizer may have some parents rethinking the parameters. The first campaign for meningococcal group B vaccine Trumenba highlights ...

Trumenba is a brand-name vaccine that is used to prevent meningitis B. It can be administered as a two-dose or three-dose schedule. More common side effects of Trumenba include pain at the injection ...

Pfizer Inc. (NYSE: PFE) disclosed the results of two stage 3 trials demonstrating the immunogenicity of TRUMENBA (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains ...

TRUMENBA® is a sterile suspension composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B ...

Pfizer Inc.PFE announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease ...

Pfizer announced that Trumenba (meningococcal group B vaccine) is now available for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in patients aged 10–25 ...

Data from both studies demonstrated the three-dose series elicits a protective immune response against diverse meningococcal group B (MenB) strains representative of prevalent strains causing invasive ...

Pfizer Inc.PFE announced positive results from two phase III studies (one in adolescents and one in young adults) on Trumenba (meningococcal group B vaccine), for providing protection against ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that TRUMENBA® (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive ...